Triple threat: new drug cocktail aims to extend life in elderly lung cancer
NCT ID NCT05685550
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This phase 2 trial is testing a combination of three drugs—oral etoposide (chemotherapy), anlotinib (targeted therapy), and envafolimab (immunotherapy)—as a first treatment for elderly patients with extensive small cell lung cancer. The study will enroll 30 participants to see if the combo helps keep the cancer from growing longer than expected. Researchers are also watching for side effects and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSION FREE SURVIVAL(PFS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, 300450, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a combination of oral etoposide (chemotherapy), anlotinib (targeted therapy), and envafolimab (immunotherapy)
What this could lead to
If successful, this could offer a new, more effective first-line treatment option for elderly patients with extensive small cell lung cancer, potentially improving how long they live without the cancer growing.
What could go wrong
This is a small, early-phase (phase 2) study with only 30 patients and no comparison group, so results may not apply broadly. The combination of three drugs also raises the risk of serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.